LINC01358: A Potential Drug Target and Biomarker (G101926925)

Target Name: LINC01358

NCBI ID: G101926925

LINC01358

Other Name(s): Long intergenic non-protein coding RNA 1358 | long intergenic non-protein coding RNA 1358

LINC01358: A Potential Drug Target and Biomarker

LINC01358 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various studies as having potential drug targets and biomarkers. This RNA molecule has a unique structure that allows it to interact with various proteins, including those that play a critical role in diseases such as cancer, diabetes, and neurodegenerative disorders.

Drug Targets

LINC01358 has been shown to interact with several proteins that are involved in various cellular processes, including cell signaling, metabolism, and stress response. One of the most promising potential drug targets for LINC01358 is the protein SMAD4, which is a key regulator of nuclear stress responses.

SMAD4 is a transcription factor that plays a critical role in ensuring that stress-induced gene expression is regulated in a timely manner. Studies have shown that LINC01358 can interact with SMAD4 and that this interaction may be involved in the regulation of cellular processes such as stress response, DNA damage repair, and cell growth.

In addition to its potential interaction with SMAD4, LINC01358 has also been shown to interact with several other proteins that are involved in drug resistance, including TP53 and p53, which are known to play a critical role in the regulation of DNA damage repair.

Biomarkers

LINC01358 has also been shown to be involved in the regulation of cellular processes that are associated with various diseases, including cancer, neurodegenerative disorders, and diabetes. For example, studies have shown that LINC01358 can be overexpressed in cancer cells and that this overexpression is associated with poor prognosis.

In addition, LINC01358 has also been shown to be involved in the regulation of cellular processes that are associated with neurodegenerative disorders, such as the regulation of neurotransmitter synthesis and the control of neurotransmitter clearance.

Methods

To study the potential drug targets and biomarkers of LINC01358, researchers have used a variety of techniques, including RNA sequencing, stable isotope labeling with amino acids in cell culture (SILAC), and biochemical assays to determine the interaction of LINC01358 with various proteins.

Conclusion

In conclusion, LINC01358 is a long intergenic non-protein coding RNA that has been identified as having potential drug targets and biomarkers. The interaction of LINC01358 with proteins involved in cell signaling, metabolism, and stress response, as well as its involvement in the regulation of cellular processes associated with diseases such as cancer, neurodegenerative disorders, and diabetes, make it an attractive candidate for further study. Further research is needed to determine the full potential of LINC01358 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1358

The "LINC01358 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01358 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets